‘Fast Money Halftime Report’ Picks For September 8
On CNBC's "Fast Money Halftime Report," Jon Najarian said the October $65 calls and the October $70 calls in Bristol-Myers Squibb Co (NYSE: BMY) were extremely active on Wednesday.
The Daily Biotech Pulse: Cellect Jumps On First Apograft Transplantation, AstraZeneca, European Commission Bury Legal Hatchet, Cassava Defends Itself
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Sept. 2)
The Daily Biotech Pulse: Cara’s Korsuva Greenlighted By FDA, Clinical Trial Disappointments For Novartis, Theravance, Vertex Inks CRISPR Licensing Deal
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 23)
Stocks That Hit 52-Week Highs On Friday
Before 10 a.m. ET on Friday, 52 companies hit new 52-week highs.
The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen’s Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 19)
10 Biggest Price Target Changes For Monday
Jefferies raised the price target on Tesla, Inc. (NASDAQ: TSLA) from $700 to $850.. Tesla shares rose 1.5% to $709.51 in pre-market trading.
Credit Suisse Maintains Outperform on Zoetis, Raises Price Target to $230
Credit Suisse analyst Katie Tryhane maintains Zoetis (NYSE:ZTS) with a Outperform and raises the price target from $206 to $230.
Barclays Maintains Overweight on Zoetis, Raises Price Target to $235
Barclays analyst Balaji Prasad maintains Zoetis (NYSE:ZTS) with a Overweight and raises the price target from $208 to $235.
The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 4)
Zoetis Raises FY21 Adj. EPS Guidance From $4.42-$4.51 To $4.47-$4.55 vs $4.52 Est., Raises Sales Guidance From $7.5B-$7.625B To $7.625B-$7.7B vs $7.59B Est.
Increases Full Year 2021 Revenue Guidance to $7.625 - $7.700 Billion and Diluted EPS of $4.09 - $4.19 on a Reported Basis, or $4.47 - $4.55 on an